Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) presented new efficacy and safety data for ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist being developed for pediatric patients with Tourette syndrome.